Oral clodronate improves the quality of life in lung cancer patients with bone metastases

1992 ◽  
Vol 17 ◽  
pp. S28
Author(s):  
H. Puolijoki ◽  
K. Liippo
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Lung Cancer Patients ◽  
Oral Clodronate

scholarly journals Bone Metastases in Lung Cancer

2021 ◽  
Author(s):  
Ana C. Belzarena
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Current Treatment ◽  
Common Symptom ◽  
Lung Cancer Patients ◽  
Skeletal Related Events ◽  
And Function

Lung cancer patients frequently present with to bone metastases. Such lesions are responsible for increased morbidity, low quality of life, and increased costs to patients and the health care system. Pain is the most common symptom; however, these lesions also present as skeletal related events (SRE) which include pathological fractures, hypercalcemia, spinal cord and nerve compressions and cause the need for surgery and/or radiotherapy. Even though bone metastases are associated with poor prognosis, current treatment multimodalities continue to improve survival. Awareness and effective treatment of these lesions is paramount to maintain a good quality of life and function in lung cancer patients.

Economic value of zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer: The case of the United Kingdom (UK)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6617-6617 ◽  
Author(s):  
M. F. Botteman ◽  
I. Foley ◽  
A. A. Marfatia ◽  
J. Brandman ◽  
C. J. Langer
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Zoledronic Acid ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Lung Cancer Patients ◽  
Life Years ◽  
Wide Range ◽  
The Impact

6617 Objectives: Zoledronic acid (ZA) reduces the risk of skeletal-related events (SREs) in lung cancer patients with bone metastases and may improve survival among those patients with high levels of bone metabolism. This analysis assessed, from the UK National Health Service's perspective, the economic impact of ZA therapy in patients with bone metastases secondary to lung cancer. Methods: A literature-based decision analytic model was developed to compare the direct costs and quality adjusted life years (QALY) experienced by lung cancer patients with bone metastases receiving placebo or ZA. Survival, SRE incidence, and number of infusions administered were obtained from a randomized clinical trial comparing 4 mg ZA with placebo. Drug acquisition and administration costs and SRE costs were estimated using published sources and national fee schedules (i.e., NHS reference costs, British National Formulary, Personal Social Services Research Unit reference costs). The impact of SREs on quality of life was estimated using the literature. Consistent with previous economic analyses of bisphosphonates in cancers (e.g., Hillner et al, 2000), patients avoiding SREs were assumed to experience quality of life improvements for 1 month. Results: The average remaining life expectancy was conservatively assumed equal in both groups and was 8.50 months (median, 5.89 months). During those months, patients receiving placebo were projected to experience 2.07 SREs on average compared to 1.32 SREs among ZA patients. QALYs were estimated at 0.3523 per patient (pp) and 0.3350 pp in the ZA and placebo groups, respectively. ZA drug-related costs were estimated at £1,473 pp, based on 5.87 infusions pp and a cost of £251.01 per infusion. The use of ZA was associated with a reduction of £1,562 pp in SRE costs. Overall, ZA saved costs and increased QALYs compared to no therapy, by £89 pp and 0.0173 QALYs pp, respectively. In sensitivity analyses, ZA cost £25,000 or less per QALY under a wide range of assumptions. Conclusions: The use of ZA leads to fewer SREs, better estimated quality of life, and lower costs relative to placebo in UK lung cancer patients with bone metastases. The use of ZA in this population therefore appears highly cost effective. No significant financial relationships to disclose.

scholarly journals Integrative Treatment of Lung Cancer Patients: Observational Study of 57 Cases

2021 ◽  
Author(s):  
Lorenzo Anelli ◽  
Alessia Di Nardo ◽  
Massimo Bonucci
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Nutritional Status ◽  
Cancer Patients ◽  
Immune Status ◽  
Conventional Medicine ◽  
Integrative Therapy ◽  
Lung Cancer Patients ◽  
Retrospective Clinical Study

Abstract Introduction A retrospective clinical study was performed to identify the characteristics of patients with lung cancer treated with integrative cancer treatment in addition to conventional medicine. Materials and Methods We reviewed medical records for lung cancer patients who visited a single integrative setting in Rome, Italy. A total of 57 patients were included, and the majority had advanced-stage cancer. All of them underwent integrative therapy with nutrition and phytotherapy indications. The diet was designed to reduce most of possible factors promoting cancer proliferation, inflammation, and obesity. Foods with anti-inflammatory, prebiotic, antioxidant, and anticancer properties had been chosen. Herbal supplements with known effects on lung cancer were prescribed. In particular, astragal, apigenine, fucosterol, polydatin, epigallocatechin gallate, cannabis, curcumin, and inositol were used. Furthermore, medical mushrooms and other substances were used to improve the immune system and to reduce chemotherapy side effects. Five key parameters have been evaluated for 2 years starting at the first surgery: nutritional status, immune status, discontinuation of therapy, quality of life, and prognosis of the disease. Results A relevant improvement in parameters relative to nutritional status, immune status, and quality of life has been observed after integrative therapy compared with the same parameters at the first medical visit before starting such approach. Conclusion The results suggest that integrative therapy may have benefits in patients with lung cancer. Even though there are limitations, the study suggests that integrative therapy could improve nutritional status and quality of life, with possible positive effect on overall survival.

scholarly journals PCN115 Quality of Life in Lung Cancer Patients During Adjuvant or Palliative Chemotherapy

2012 ◽  
Vol 15 (7) ◽  
pp. A430
Author(s):  
L.M. Wintner ◽  
A. Zabernigg ◽  
J.M. Giesinger ◽  
M. Sztankay ◽  
K. Gattringer ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Palliative Chemotherapy ◽  
Lung Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document